Naso-ratiopharm

Naso-ratiopharm nasal spray helps you breathe easier through your nose by reducing swelling in the lining of your nose and throat caused by a runny nose.

Form
nenäsumute, liuos
Strength
1 mg/ml
Active Ingredient
Xylometazoline hydrochloride
Manufacturer
ratiopharm GmbH

How to Use

Dosage

For adults and children over 10 years old: One spray into each nostril. For children 2-10 years old: One spray into each nostril (using the 0.5 mg/ml strength).

Method

First, gently blow your nose. Hold the bottle upright, insert the nozzle into one nostril, and spray once while breathing in. Repeat for the other nostril.

Important

Use up to three times a day. Do not use for more than 7 consecutive days (for 1 mg/ml strength) or 5 consecutive days (for 0.5 mg/ml strength).

Possible Side Effects

COMMON
  • Burning sensation in the nose lining
  • Dryness in the nose lining
RARE
  • Allergic reactions (e.g., swelling of the face/throat, rash, itching)
  • Heart palpitations
  • Fast heart rate
  • High blood pressure
  • Irregular heartbeat
  • Hallucinations (mostly in children)
  • Seizures (especially in children)
  • Temporary vision problems
  • Irritation in the nose, mouth, and throat
  • Nosebleeds
  • Nervousness
  • Sleep problems
  • Tiredness (drowsiness, reduced alertness)
  • Headache
  • Dizziness
  • Nausea

Important Warnings

  • Do not use if you are allergic to xylometazoline or any other ingredients in this medicine.
  • Do not use this medicine for more than the recommended days, as long-term use can make your nose more congested.
  • Talk to your doctor before use if you have high blood pressure, heart disease, diabetes, or an overactive thyroid.
  • Do not use if you are taking or have recently taken (within 14 days) certain antidepressant medicines called MAO inhibitors.
  • This medicine is not for children under 10 years old (1 mg/ml strength) or under 2 years old (0.5 mg/ml strength).

Use in Elderly Patients

Category A

Suitable for older adults. For short-term use only. (updated 17.2.2025)